News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,048 Results
Type
Article (13963)
Company Profile (304)
Press Release (247781)
Section
Business (79389)
Career Advice (151)
Deals (13194)
Drug Delivery (34)
Drug Development (50352)
Employer Resources (31)
FDA (5697)
Job Trends (5120)
News (144212)
Policy (10022)
Tag
Academia (901)
Alliances (21540)
Alzheimer's disease (761)
Approvals (5683)
Artificial intelligence (70)
Bankruptcy (97)
Best Places to Work (4526)
Biotechnology (249)
Breast cancer (110)
Cancer (897)
Cardiovascular disease (71)
Career advice (132)
CAR-T (74)
Cell therapy (218)
Clinical research (40176)
Collaboration (313)
Compensation (129)
COVID-19 (1007)
C-suite (79)
Cystic fibrosis (67)
Data (986)
Diabetes (87)
Diagnostics (1210)
Drug discovery (57)
Earnings (29016)
Events (47230)
Executive appointments (249)
FDA (6077)
Funding (311)
Gene editing (64)
Gene therapy (164)
GLP-1 (311)
Government (1065)
Healthcare (6551)
Infectious disease (1045)
Inflammatory bowel disease (98)
IPO (7200)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (133)
Lymphoma (62)
Manufacturing (87)
Medical device (2583)
Medtech (2584)
Mergers & acquisitions (6136)
Metabolic disorders (262)
Neuroscience (1007)
NextGen Class of 2024 (2008)
Non-profit (849)
Northern California (1101)
Obesity (142)
Opinion (92)
Parkinson's disease (78)
Patents (63)
People (25117)
Phase I (14160)
Phase II (18678)
Phase III (11832)
Pipeline (367)
Postmarket research (853)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (204)
Real estate (1410)
Regulatory (8298)
Research institute (931)
Southern California (985)
Startups (1965)
United States (8740)
Vaccines (165)
Weight loss (84)
Date
Today (10)
Last 7 days (33)
Last 30 days (1258)
Last 365 days (20558)
2024 (20558)
2023 (22423)
2022 (26846)
2021 (27821)
2020 (23367)
2019 (16233)
2018 (11751)
2017 (13760)
2016 (11846)
2015 (14361)
2014 (10409)
2013 (7505)
2012 (7544)
2011 (7636)
2010 (7433)
Location
Africa (146)
Asia (16935)
Australia (2857)
California (2495)
Canada (817)
China (208)
Colorado (93)
Connecticut (105)
Europe (36487)
Florida (273)
Georgia (71)
Illinois (154)
Indiana (63)
Maryland (336)
Massachusetts (1968)
Michigan (58)
Minnesota (101)
New Jersey (639)
New York (692)
North Carolina (420)
Northern California (1101)
Ohio (82)
Pennsylvania (478)
South America (207)
Southern California (985)
Texas (282)
Washington State (249)
262,048 Results for "flexion therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Deals
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
Pacira BioSciences, Inc. and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash.
October 11, 2021
·
21 min read
Genetown
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference.
September 3, 2021
·
1 min read
Business
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors.
July 12, 2021
·
5 min read
Business
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2021.
August 4, 2021
·
14 min read
Genetown
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021
Flexion Therapeutics, Inc. announced equity inducement grants to three new employees consisting of 6,315 restricted stock units.
October 1, 2021
·
1 min read
Business
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET.
July 29, 2021
·
1 min read
Business
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.
May 12, 2021
·
14 min read
Genetown
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference.
June 14, 2021
·
1 min read
Drug Development
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy.
August 25, 2021
·
4 min read
1 of 26,205
Next
